Raise Growth Capital

Updated Q3 2026 by CT Acquisitions.

If you run a profitable lower middle market business generating $1M to $25M of EBITDA and want to raise growth capital without giving up control or selling outright, this guide is the plain-English map of what the 2026 market actually offers. It names the sponsors, prices the dilution, walks the process, and shows where a minority recap beats a full sale, a senior loan, or a Series B.

What does it mean to raise growth capital?

To raise growth capital means to sell a minority equity stake in a profitable business, usually 20% to 40%, in exchange for cash that funds expansion, acquisitions, or partial owner liquidity. It differs from venture capital because the company is already profitable, and it differs from a full sale because founders keep majority ownership and operating control. Institutional sponsors like Summit Partners and TA Associates price these deals on trailing EBITDA, not on projected ARR.

Growth capital sits in a distinct box on the capital stack. It is equity, but not the equity of a venture Series B where the company burns cash to prove product-market fit. It is minority equity for a business that already has product-market fit, positive cash flow, and a specific plan to spend money on growth: opening new geographies, adding a sales team, buying up smaller competitors, integrating an ERP, or hiring a Chief Revenue Officer who costs $500K fully loaded.

The industry uses several near-synonyms, and the differences matter. Growth equity historically referred to institutional minority investments in software and tech-enabled services companies with $10M to $100M of revenue growing 30% or more per year. Growth capital is the broader term the LMM uses for the same product applied to industrials, healthcare services, business services, and consumer brands. Structured growth or non-control preferred describes the same thing when the security is a preferred instrument rather than common equity.

A useful mental model: if a bank will not lend you enough to accomplish the plan because you would exceed 4.0x total leverage or trip a fixed-charge ratio, and you do not want to sell the whole company, growth capital fills the gap. According to PitchBook’s Q4 2024 US PE Breakdown, US private equity firms deployed $838.5 billion across 8,473 deals in 2024, with growth equity strategies accounting for a rising share of new fund formation as buyout multiples compressed and sponsors adapted to the higher rate environment.

Who typically raises growth capital in the LMM?

LMM operators who raise growth capital are usually second-generation family owners, founder-led businesses at $10M to $100M revenue, or management teams who bought their company through an MBO five to ten years ago. They tend to have $2M to $15M of EBITDA, positive cash flow, defensible customer relationships, and a growth plan too large for their balance sheet. Family offices like Pritzker Private Capital and growth funds like Providence Strategic Growth are the natural buyer set.

Three archetypes make up the bulk of growth capital raisers we see at CT Acquisitions. The first is the founder in their fifties or sixties who built a business over 20 to 30 years, wants to take some chips off the table without retiring, and needs a partner to institutionalize the company for the next stage. This person is not a startup founder and would find the Silicon Valley pitch cadence alien.

The second is the second-generation family owner who inherited or bought out siblings and now wants to accelerate. Family businesses represent roughly 60% of US GDP and 78% of new jobs created according to the Family Business Magazine survey of the 2024 landscape, and a growing share are looking at outside minority capital as a way to fund growth without triggering a sibling liquidity fight.

The third is the management team that closed an MBO five to ten years ago, paid down the acquisition debt, and now wants a growth partner to fund a rollup thesis. These deals often bring in a sponsor like Summit Partners or TA Associates as a minority partner while management retains majority ownership. See our companion guide on the lower middle market M&A advisor role for the advisor-selection framework.

How does growth capital compare to venture capital, private equity, and debt?

Growth capital sits between venture capital (early stage, unprofitable, ARR-priced) and control private equity (majority buyout, 100% of the equity). It differs from debt because there is no fixed repayment obligation and no interest coverage covenant. A $10M growth check at 6.0x EBITDA post-money would dilute the founder by roughly 28%, while a $10M unitranche loan at SOFR plus 550 basis points would add roughly $850K of annual interest but no dilution.

The right frame is the capital stack. Senior debt from a bank or BDC is cheapest at SOFR plus 250 to 450 basis points but is capped by cash-flow multiples that rarely allow more than 3.0x to 4.0x total leverage on an LMM business. Unitranche adds another turn or two of leverage at SOFR plus 550 to 700 basis points. Mezzanine sits above that with a 10% to 13% cash coupon plus warrants. Preferred equity comes next, and common growth equity is the most expensive capital because it is the most junior and demands the highest return.

Capital source	Cost (all-in IRR to provider)	Dilution	Repayment/exit obligation	Best fit
Senior bank debt	SOFR + 250 to 450 bps (~8% to 10%)	None	Amortizing, 5 to 7 year term, cash covenants	Recurring cash flow, 2.5x to 3.5x total leverage
Unitranche/BDC	SOFR + 550 to 700 bps (~11% to 13%)	None (rare small warrant)	Bullet or 1% amort, 5 to 7 year term	Sponsor-backed LBOs, 4.0x to 5.0x leverage
Mezzanine debt	10% cash + 2% PIK + warrants (~15% to 18%)	Small (warrants 2% to 8%)	Interest only, bullet at year 7	Gap financing above senior, LBO capital stack
Preferred equity (structured)	Coupon 8% to 12% + participation (~15% to 20%)	Modest (10% to 20%)	Redemption right after 5 to 7 years	Founder wants low dilution, willing to service coupon
Growth common/minority	Targeted IRR 22% to 30%	20% to 40%	None; exit at year 4 to 7 via sale, IPO, or continuation	Growth plan needs equity for M&A or S&M spend
Venture capital (Series B/C)	Targeted IRR 30% to 50%+	20% to 35% per round	Preferred stack, participation, ratchets	Pre-profit or high-growth SaaS/tech, ARR-priced
Control PE buyout	Targeted IRR 20% to 25%	100% (founder can roll 10% to 40%)	Exit at year 4 to 6 via sale or dividend recap	Owner exit, professional management transition

For a fuller breakdown by instrument, see the CT primers on growth equity versus private equity, mezzanine debt for acquisitions, and unitranche debt acquisition financing.

When does it make sense to raise growth capital?

Raising growth capital makes sense when three conditions line up: the business is profitable enough that a bank could lend to it, the growth plan requires more capital than debt can safely fund, and the owner is willing to accept a board seat and a defined liquidity path in year 4 to 7. A furniture retailer at $4M EBITDA planning a five-state expansion, or a healthcare services roll-up at $8M EBITDA planning to acquire three regional add-ons, fit the pattern.

Growth capital does not make sense for four situations we routinely turn away. The first is a business under $1M of EBITDA. The economics of a professional raise, the fees, the diligence, the sponsor governance, do not work below that scale, and the buyer set thins out sharply. Angel networks, SBA lending, or a strategic partnership are usually the better answer.

The second is an owner who is unwilling to accept any dilution or governance. If the answer to “are you comfortable with a board seat and consent rights?” is no, you should stop and revisit debt options. Read the CT guide on business acquisition loans and mezzanine before pursuing minority equity.

The third is a business in secular decline. A rural newspaper, a print-focused directory business, a legacy call center with declining volumes: sponsors will not price these on 6.0x forward EBITDA because forward EBITDA is falling. The fourth is an owner who wants full liquidity in 6 months. That is a sale process, and the right document to read is the CT overview of M&A advisory services.

In our experience advising LMM operators through a growth capital raise, the single biggest predictor of a good outcome is not the multiple. It is whether the founder has a specific, dollar-quantified use of proceeds that a sophisticated investor can underwrite. “We want to grow” loses every negotiation. “We need $12M: $6M to acquire two regional competitors already in LOI, $4M to fund a national sales team on a 24-month payback, and $2M for ERP integration” wins every negotiation. Sponsors pay premium multiples for specificity because it lowers their execution risk.

How much does it cost to raise growth capital?

A typical LMM growth raise costs 4% to 6% of the equity raised in advisor fees plus $150K to $350K in third-party diligence costs (QoE, legal, tax). The bigger cost is dilution: a $15M raise at a $50M post-money valuation dilutes the founder by 30%. Sponsors also charge a management fee of 1% to 2% of committed capital annually to their LPs, but this does not come out of the operating company.

Cost category	Typical range (LMM raise)	Notes
Capital advisor / M&A banker success fee	4% to 6% of equity raised (modified Lehman)	Retainer of $25K to $50K/mo, credited
Quality of Earnings (QoE) report	$60K to $150K	Sponsors will insist on Big 4 or top LMM firm
Legal fees (issuer counsel)	$150K to $350K	Higher if complex tax structure or IP carveouts
Tax structuring advisory	$25K to $75K	Especially for S-corp to C-corp or F-reorg
Environmental / IT / commercial diligence	$40K to $120K	Often reimbursed by sponsor at close
Founder dilution (economic cost)	20% to 40% of equity	Largest true cost; math varies by valuation
Post-close reporting infrastructure	$100K to $300K/yr ongoing	Monthly reporting package, board meetings, audit

The dilution math is worth walking. Take a business at $5M of trailing EBITDA raising $12M of primary growth equity at a $50M post-money enterprise value. The pre-money is $38M, so the sponsor takes 24% of the equity at close. If the business grows to $15M of EBITDA in five years and exits at 9.0x, the enterprise value would be $135M. The sponsor’s 24% is worth roughly $32.4M gross, netting a 3.6x MOIC and roughly 29% IRR before fees, which is exactly what a growth equity fund underwrites to.

Bain’s Global Private Equity Report 2025 tracked LMM growth returns holding up better than large-cap buyout returns in the 2024 vintage, with median growth equity returns of 2.4x MOIC across the North American sample, reinforcing that sponsors will continue to pay for scaled-up LMM assets.

Who provides growth capital to LMM operators?

Growth capital providers to LMM operators fall into four buckets: dedicated growth equity funds (Summit Partners, TA Associates, Providence Strategic Growth), family offices with growth mandates (Pritzker Private Capital, BDT Capital Partners, Waud Capital), BDCs and structured capital funds (Main Street Capital, Golub Capital), and independent sponsors backing management teams. Check sizes span $5M for lower-end structured minority deals to $150M+ for platform growth investments.

Sponsor / firm	Type	Typical check size	Focus
Summit Partners	Growth equity fund	$15M to $200M	Growth-stage tech, healthcare, financial services; minority and control
TA Associates	Growth PE	$50M to $500M	Tech, healthcare, financial services, consumer; global platform
Providence Strategic Growth (PSG)	Growth equity	$10M to $100M	Founder-led software and tech-enabled services in the LMM
Pritzker Private Capital	Family capital	$50M to $500M	North American manufacturing, services, and healthcare; permanent capital
BDT & MSD Partners	Family / merchant bank	$50M to $1B+	Family- and founder-owned businesses; long-duration capital
Waud Capital Partners	Middle-market PE	$25M to $250M	Healthcare services and business services, growth and buyout
Main Street Capital	BDC (public)	$5M to $75M	LMM debt and equity co-invest; one-stop structured capital
Golub Capital	Private credit / BDC	$20M to $500M	Unitranche and structured minority equity to sponsored LMM

The choice among these buckets matters. Growth equity funds like Summit and TA underwrite a 4- to 6-year hold to a defined exit and will push the company toward institutional discipline, monthly board packages, audit committees, three-year strategic plans. Family offices like Pritzker and BDT are more patient, sometimes indefinite in their hold horizon, and can be a better fit for owners who value continuity over speed. BDCs like Main Street Capital or Golub Capital offer flexibility on structure but tend to underwrite tighter governance packages.

For an in-depth compare of family office versus institutional PE approaches, see the CT guide on family office versus PE buyer, and on the differences between selling equity to a growth investor versus a control buyer, see selling to a growth equity investor.

How does the growth capital raise process actually work?

A well-run LMM growth capital raise moves through eight distinct phases over 5 to 8 months: advisor selection, preparation and materials, buyer list development, launch and marketing, indications of interest, management presentations, term sheets and selection, then confirmatory diligence and close. A competitive process with 25 to 40 targeted sponsors typically yields 6 to 12 indications and 3 to 5 term sheets to negotiate against each other.

1. Advisor engagement (weeks 1 to 2). Sign the engagement letter, define fee structure, and set the buyer universe hypothesis. Retainer of $25K to $50K per month begins.
2. Preparation (weeks 3 to 8). Build the confidential information memorandum (CIM), the financial model with three-statement projections, the management presentation, and the data room. Commission a QoE if not already done.
3. Buyer list (weeks 6 to 9). Refine the target list to 25 to 40 named sponsors. Overlap with the founder’s known relationships and eliminate any hard no-go firms.
4. Launch and marketing (weeks 9 to 12). Send teasers under NDA. First-round CIM goes to signed NDAs. Advisor takes 30 to 60 sponsor calls over three weeks to answer initial questions.
5. Indications of interest (weeks 12 to 15). Sponsors submit non-binding IOIs with valuation ranges, structure preferences, and diligence needs. Advisor grades the IOIs and shortlists 6 to 10 for management meetings.
6. Management presentations (weeks 15 to 18). Each shortlisted sponsor gets a 3- to 4-hour in-person or hybrid session with the CEO, CFO, and often a functional lead. Advisor facilitates follow-up diligence questions.
7. Term sheets and selection (weeks 18 to 22). Sponsors submit binding term sheets. Advisor negotiates valuation, board composition, protective provisions, liquidation preference, ROFR, and drag rights. Founder selects one sponsor.
8. Confirmatory diligence and close (weeks 22 to 32). Selected sponsor completes confirmatory diligence: financial (Big 4 QoE review), legal (SPA and disclosure schedules), tax (F-reorg or S-corp step-up if applicable), commercial (customer calls), IT, and environmental. Documents get finalized, funds get wired.

The compression opportunities are the QoE (a clean, pre-completed QoE done by a top-tier firm can cut the diligence phase by 30 to 45 days) and legal readiness (having disclosure schedules pre-built for the standard SPA cuts another two weeks). Deals that skip preparation and go direct-to-market average 9 to 11 months to close, not 5 to 8.

What paperwork and documentation does a growth capital raise require?

A growth capital raise typically requires four categories of documents: internal financials (audited or reviewed statements for 3 years, monthly management accounts, working capital roll), diligence deliverables (QoE, tax memo, cap table, customer concentration analysis), transaction documents (term sheet, SPA, shareholders agreement, employment agreements), and post-close reporting (monthly management reports, quarterly board packages, annual audit).

The internal financials come first because everything else builds on them. Sponsors expect three years of GAAP or reviewed financial statements, ideally with a prior-period audit. If the business has been on cash-basis or has a bookkeeper-run chart of accounts, the first job is to convert to accrual and get an outside firm to review or audit. This typically takes 60 to 90 days and costs $30K to $75K for an LMM company.

The diligence deliverables include the QoE, which is the single most important document in the process. A QoE prepared by a top-10 firm (Alvarez & Marsal, Deloitte, EY-Parthenon, PwC, RSM, BDO) will validate EBITDA add-backs, normalize working capital, and flag risks. Sponsors would typically insist on a QoE reviewed or refreshed by their own diligence provider, but a clean starting point saves weeks.

The transaction documents include the term sheet (5 to 15 pages, non-binding), the stock purchase or subscription agreement (SPA, 60 to 120 pages), the shareholders or investors rights agreement (30 to 60 pages), and various ancillary documents including employment agreements for key executives, non-compete agreements, escrow agreements, and disclosure schedules. For a walkthrough of the deal-defining document, see the CT explainer on what is a term sheet.

What are the tax and legal implications of raising growth capital?

The main tax question is whether to structure as a primary equity issuance (no immediate tax to the seller because no shares are sold) or a secondary sale (capital gains tax on shares sold at close). Structure choice depends on entity type: S-corp sellers often use an F-reorganization to convert to a C-corp structure that lets the sponsor take a stepped-up basis, while pass-through partnerships can accept a section 754 election. A cross-border sponsor may trigger CFIUS review.

For an S-corporation, the F-reorganization is the standard playbook when a growth investor wants a stepped-up basis for a portion of the equity. The seller drops the operating S-corp into a new LLC, contributes the LLC interests to a new C-corp, and the sponsor then invests in the C-corp. The F-reorg is tax-neutral to the seller if done correctly and lets the sponsor amortize a portion of the purchase price. This is technical work; you need a tax attorney and an accounting firm that has done at least 10 of these.

Section 1202 (qualified small business stock, or QSBS) is worth mentioning for founders whose operating business is or can be a C-corp. Under current law, a founder who has held C-corp stock for 5 years may exclude up to $10M or 10x basis of gain at exit. A growth capital raise that pushes the company through the C-corp conversion can, if planned carefully, preserve or start the QSBS clock. See the IRS guidance in Instructions for Form 8949 and consult a tax attorney.

On the legal side, key issues include state blue-sky filings under Rule 506(b) or 506(c) of Regulation D, HSR pre-merger notification if the deal size crosses the 2026 threshold of $126.4M per the FTC’s 2025 HSR threshold update, and CFIUS review if any portion of the sponsor’s capital is foreign-sourced or if the target operates in a covered sector. Cross-border LMM deals now trigger CFIUS review more often since the 2024 expansion of covered real estate zones.

What are the common structures and terms in a growth capital deal?

Common structures include convertible preferred stock with 1x non-participating liquidation preference, minority common equity, and structured preferred with a coupon and redemption right. Standard terms include a board seat proportional to ownership, protective provisions (consent rights on new debt, major asset sales, CEO change), a ROFR on future share sales, tag-along and drag-along rights, and a defined liquidity path via IPO, sale, or continuation vehicle by year 5 to 7.

Deal term	Standard LMM growth capital range	Founder-favorable variant	Sponsor-favorable variant
Liquidation preference	1x non-participating	Common only; no preference	1.5x participating capped at 3x
Anti-dilution	Broad-based weighted average	None or narrow-based	Full ratchet
Board composition (25% investor)	1 investor seat, 3 founder/mgmt seats, 1 independent	1 observer only	2 investor seats, right to appoint chair
Protective provisions	Standard 10 to 12 items	5 to 7 items only, high thresholds	Expanded to include annual budget approval, capex over $250K
Drag-along threshold	50% approval, sponsor participation required	75% approval, minimum valuation floor	Sponsor unilateral after year 5
ROFR / co-sale	ROFR on founder sales above 5% of stock	ROFR only, no co-sale	Full co-sale on any founder liquidity
Dividend	None (common); 8% PIK (preferred)	None	8% to 10% cumulative cash if not paid
Redemption	Optional after year 5, at cost + accrued	Optional after year 7, no premium	Mandatory after year 5, at accreted value
Registration rights	Demand after IPO, 2 demands, unlimited piggyback	Piggyback only	Demand at any time after year 3, unlimited

Two structures deserve special attention for LMM operators. The first is structured preferred equity with a coupon, which behaves halfway between debt and equity. The sponsor gets an 8% to 12% cumulative coupon (paid in cash or PIK), a redemption right after 5 to 7 years, and modest equity participation (10% to 20% of the pro forma common). This can be attractive for founders who want to minimize dilution and are willing to service the coupon.

The second is the minority recap, where the raise combines primary (growth) and secondary (owner liquidity). A common blend: on a $30M raise at $75M post-money, $12M is primary going to the balance sheet for growth and $18M is secondary going to the founder as capital gains at close. The founder gets meaningful liquidity, keeps 60% ownership, and still funds the growth plan.

What are the red flags to avoid in a growth capital raise?

The five biggest red flags in a growth capital raise are: skipping a QoE and getting repriced during diligence, accepting a term sheet from a single-buyer negotiation without a competitive process, agreeing to a full ratchet anti-dilution provision, ceding CEO removal rights to the investor board seat, and taking a check from an unfunded independent sponsor without confirmed limited-partner commitments. Each has cost LMM sellers 15%+ of value in recent transactions.

The single-buyer trap is the most common. An owner takes a call from a family friend who runs a family office, gets a term sheet at 5.5x EBITDA, and signs it because it feels like a warm relationship. In our experience, a competitive process with 25 to 40 sponsors typically clears at 6.5x to 7.5x for the same asset, meaning the owner left 20% to 35% of value on the table for the perceived comfort of a known counterparty.

The QoE-during-diligence trap is the second most common. A sponsor issues a term sheet at 6.5x EBITDA based on management-reported numbers. Confirmatory diligence discovers $700K of add-backs that do not survive scrutiny. The sponsor either walks or repriices to 5.8x on the “true” EBITDA. Having a clean, sponsor-quality QoE done in advance prevents this. It costs $60K to $150K and typically saves $500K to $2M of price erosion.

The unfunded independent sponsor issue is subtler. Independent sponsors are individuals or small teams who source deals and then raise LP capital deal-by-deal. Many are excellent operators, but some sign term sheets and then fail to raise the LP equity. If you are accepting a term sheet from a firm not marked as “fund” on EDGAR, verify committed capital before pulling your process off the market.

What are the 2024-2026 market dynamics for LMM growth capital?

The 2024-2026 LMM growth market is characterized by three dynamics: record US PE dry powder of $1.20 trillion at 2024 year-end per PitchBook, compressed buyout leverage due to SOFR at 4.3% at mid-2025 pushing sponsors toward less-levered growth strategies, and rising median LMM valuations (GF Data reported 8.0x average TEV/EBITDA in H1 2025). Family offices and BDCs have gained share as banks tightened lending standards.

The dry-powder overhang is real but has to be weighed against the fund vintage math. According to Bain’s Global Private Equity Report 2025, roughly one-third of PE dry powder is aging (three years old or older) and faces investment pressure. That has driven a rebound in LMM deal activity in 2025, with the North American middle-market segment leading the recovery.

The rate environment shapes structure. With SOFR still around 4.3% at mid-2025 (see the New York Fed SOFR data), unitranche loans priced at SOFR + 600 clear at roughly 10.3% all-in, which caps leverage buyers can support. This has shifted LMM capital raises from majority-control LBOs toward minority growth structures where sponsor return is driven by growth rather than leverage.

Named-comp examples from 2024 to 2026 to anchor the discussion: in July 2025, Providence Strategic Growth announced a minority growth investment in a founder-led software company, with press coverage citing a valuation in the mid-teens revenue multiple range. In November 2024, Axial’s H1 2024 LMM Multiples report flagged healthcare services and specialty industrials as the highest-multiple LMM verticals. Deal activity data from PitchBook Q4 2024 shows LMM software minority growth deals clearing 4.5x to 8.0x forward revenue for high-growth assets.

McKinsey’s 2025 view of private markets, in the Global Private Markets Report 2025, highlighted a “flight to quality” in 2024 where the top quartile of LMM assets attracted disproportionate capital and cleared at premium multiples, while lower-quality assets sat on the market. For a sober macro read on structured minority activity, see PwC’s Deals 2025 Outlook, which flagged growth-equity minority checks as one of the recovery vectors for LMM activity.

How does CT Acquisitions help you find the right equity partner?

CT Acquisitions runs a capital-raise process for LMM operators with $1M to $25M of EBITDA. The team builds the buyer list, prepares the CIM and QoE, launches to 25 to 40 targeted sponsors, negotiates term sheets, and manages diligence to close. The differentiator is buyer selection: CT matches operators with sponsors whose fund thesis, hold horizon, and governance philosophy fit the founder’s post-close preferences, not just the highest headline valuation.

The CT approach to a growth capital raise starts with a diagnostic. Before signing an engagement letter, a CT capital advisor spends 2 to 3 hours with the founder to map the raise size, the use of proceeds, the founder’s post-close role preference, the willingness to accept a board seat, the tolerance for structured versus common equity, and the desired hold horizon of the counterparty. This diagnostic determines whether growth capital is even the right product, or whether a senior loan, a mezzanine tranche, or a full sale is a better fit.

From there, CT builds the buyer list. Instead of blasting 200 sponsors, CT typically targets 25 to 40 firms whose stated thesis matches the company. For a $5M-EBITDA healthcare-services roll-up, the list might include Waud Capital, PSG, three or four regional healthcare-services family offices, and two structured-capital funds. For a $10M-EBITDA industrial services business, the list would include Pritzker Private Capital, three growth funds with industrials teams, and two independent sponsors with committed capital.

CT’s role continues through negotiation and diligence. The advisor negotiates term sheets, drives sponsor-versus-sponsor competition, and manages the QoE and legal workstreams to close. The success fee ties the advisor’s interests to the founder’s: higher valuation and better terms drive the advisor’s compensation.

How do you choose among competing capital advisors?

Choose a capital advisor based on four criteria: proven LMM raise track record in your revenue size (ask for the last 10 deals closed and their sizes), sponsor-relationship coverage in the buyer universe relevant to your business, alignment on fee structure (retained-plus-success is standard), and cultural fit with the founder team. The wrong advisor costs 20%+ of headline value; the right one earns the fee back many times over.

The track record question is the most important and the most gameable. Ask for the last 10 closed capital raises: size of raise, industry, whether the advisor was lead or co-advisor, and the sponsor set. If the last 10 deals are all $100M+ Series C VC rounds and yours is a $10M growth capital raise for a specialty industrial, the advisor’s Rolodex is not aligned with your buyer set.

Fee alignment is the second question. Modified Lehman scales that pay 5% on the first $10M, 4% on the next $10M, and step down from there are standard. Watch for advisors who quote a flat retainer with no success fee (they are not aligned with your outcome) or a straight percentage with no minimum retainer (they may de-prioritize your deal if a larger one shows up).

Cultural fit is third but underrated. You will spend 5 to 8 months in weekly calls with this advisor, and the last month is high-stress. If the founder and the advisor lead cannot have direct conversations about hard tradeoffs, the process suffers. Interview the specific advisor who will run your deal, not the firm’s senior partner who signs the letter.

Fourth, coverage of the relevant buyer universe. Ask directly: which family offices and growth funds have you closed deals with in the last three years, and what is the current partner or principal contact? If the answer is vague, the advisor’s Rolodex is stale. See the CT guide on lower middle market M&A advisor selection for the fuller framework.

What is the difference between a growth capital raise and a leveraged buyout?

A growth capital raise sells a minority equity stake to fund growth, keeping the founder in majority control. A leveraged buyout (LBO) sells majority or all of the equity to a sponsor who funds the purchase largely with debt. Growth deals typically use 0 to 2x total leverage; LBOs typically use 4 to 5.5x. Founders in a growth deal keep operating authority; founders in an LBO usually roll 10% to 40% of their equity and take a “chairman of the board” role, not CEO.

The economics differ sharply. In a growth deal at 6.5x EBITDA post-money, the sponsor’s underwriting depends on growing EBITDA over 5 years to 2x or 3x current levels and exiting at a similar multiple. In an LBO at 8.0x EBITDA with 5.0x leverage, the sponsor’s returns come primarily from debt paydown and modest EBITDA growth, with multiple expansion providing upside.

For an operator, the question is post-close role. Growth deals leave founders in the CEO seat with a new board partner and a growth budget. LBOs typically transition operating leadership within 12 to 36 months, either to a new CEO recruited by the sponsor or to an internal COO who was groomed pre-close. See the CT guide on leveraged buyout acquisition financing for the LBO capital stack.

How does raising growth capital affect a future sale of the business?

Taking growth capital typically accelerates the timeline to a future sale by 3 to 5 years because the sponsor has a defined hold horizon and will drive toward liquidity. It usually improves the eventual sale price because the company enters the sale process with institutional governance, audited financials, and a professionalized management team, all of which command a valuation premium of 0.5x to 1.5x EBITDA. Founders who took growth capital in 2020 and sold in 2024-2025 saw median return multiples exceeding a pure hold strategy.

The mechanics work like this. A growth investor buys in at year 0 at 6.5x EBITDA, works with management for 5 years to grow EBITDA from $6M to $14M, and drives an exit at 8.5x. The company sells for $119M enterprise value. The founder’s remaining 65% equity is worth $77M gross, versus roughly $32M if they had held their 100% at year 0 without the growth partner. The math depends on execution but consistently favors institutionalized growth over stand-alone hold.

There are cases where the numbers do not favor a growth capital raise. If the business is already growing at 30% per year organically without new capital, if the founder does not need liquidity, and if the founder plans to hold indefinitely, staying independent may be the better answer. If the business is instead capacity-constrained or capital-constrained, a growth raise typically pays for itself and then some. See our companion guide on sell-side M&A advisory for how the eventual exit process differs.

Frequently asked questions

How much of my company do I have to give up to raise growth capital?

A typical LMM minority growth investment takes 20% to 40% of the equity in exchange for a check sized at roughly 4x to 7x trailing EBITDA of post-money value. Founders and management usually retain majority control, board control if they were majority pre-round, and day-to-day operating authority. Structured preferred instruments can lower dilution further at the cost of a coupon.

Is growth capital the same as venture capital?

No. Venture capital funds unprofitable early-stage software and biotech companies at pre-revenue or pre-profit valuations. Growth capital, sometimes called growth equity, funds profitable operating businesses with proven unit economics that want to accelerate. Growth sponsors like Summit Partners, TA Associates, and General Atlantic price on EBITDA and cash flow, not on ARR multiples.

How long does it take to close a growth capital raise for an LMM company?

Plan on 5 to 8 months from advisor engagement to funded close. Preparation and materials take 6 to 10 weeks, marketing to sponsors runs 6 to 8 weeks, indications and management meetings add 4 to 6 weeks, and confirmatory diligence plus documentation typically consumes another 8 to 10 weeks. Deals with a clean QoE close faster.

What is a minority recapitalization and how does it differ from a growth round?

A minority recap uses new investor equity to buy out existing shareholders and put liquidity in the founder’s pocket, while a pure growth round pushes primary capital onto the balance sheet to fund expansion. Many LMM deals blend both: a 30% stake priced at 6.5x EBITDA where two-thirds is secondary to the seller and one-third is primary for growth.

Do I need an M&A advisor or investment bank to raise growth capital?

For a raise above $10M of equity, an advisor typically pays for itself. Sell-side or capital-raise advisors run a competitive process, drive valuation, negotiate terms, and manage diligence workflow. Sponsors expect a process. Owners who go direct to a single relationship investor usually accept the first term sheet and leave 15% to 25% of value on the table.

What multiples are LMM growth deals pricing at in 2026?

GF Data reported an 8.0x average TEV/EBITDA multiple for its LMM sample in the first half of 2025, with software, healthcare services, and specialty industrials clearing double-digit multiples for high-quality assets. Growth minority stakes usually price at a modest premium to a change-of-control transaction because sponsors underwrite continued founder alignment.

Can I raise growth capital without a board seat going to the investor?

Rarely. Almost every institutional growth check comes with a board seat and standard minority protections including consent rights on new debt, budget approval, and change of CEO. Family offices are sometimes flexible on board observer versus board member, but the governance package is not a negotiation an operator wins alone.

How does CT Acquisitions get paid on a growth capital raise?

CT Acquisitions works on a retained-plus-success model typical of LMM capital advisors. A modest monthly retainer covers preparation and marketing costs, and a success fee, usually structured as a Lehman-style scale on the equity raised, pays out at close. Retainer credits against the success fee. All fees are disclosed in writing before engagement.

Related CT Acquisitions guides

• Raise Capital pillar hub
• Sell-side M&A advisory
• Buy-side M&A advisory
• Lower middle market M&A advisor
• Growth equity vs private equity
• Mezzanine debt for acquisitions
• Unitranche debt acquisition financing
• Selling to a growth equity investor
• Family office vs PE buyer
• What is a term sheet
• Business acquisition loan
• Leveraged buyout acquisition financing